Trade Names:Arcalyst- Injection, lyophilized powder for solution 220 mg
Acts as a soluble decoy receptor that binds interleukin-1β, preventing interaction with cell surface receptors.
At steady state, the average trough levels are about 24 mcg/mL.
No data available.Hepatic Function Impairment
No data available.Elderly
Age does not appear to affect trough concentrations.Gender
Based on limited data, steady state trough levels are similar between men and women.Race
Could not be assessed.
Treatment of Cryopyrin-associated periodic syndrome, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome.
Subcutaneous Two 160 mg doses as an initial loading dose, administered on the same day at 2 different sites. The weekly maintenance dose is 160 mg as single 2 mL injections.Children 12 to 17 yr of age
Subcutaneous 4.4 mg/kg as an initial loading dose (max, 320 mg) delivered as 1 or 2 injections (single-injection max, 2 mL). If the initial dose is given as 2 injections, give on the same day at 2 different sites. The weekly maintenance dose is 2.2 mg/kg (max, 160 mg) given as a single injection (single-injection max, 2 mL).
Store lyophilized product at 36° to 46°F. Protect from light. After reconstitution, keep at room temperature and use within 3 h. Protect from light.
Monitor the effects of the drug and adjust the dose as needed.Drugs that block interleukin-1, tumor necrosis factor–blocking agents
Coadministration with these agents is not recommended.Live vaccines
Coadministration of live vaccines is not recommended. Vaccinations may not be effective.
None well documented.
Injection-site reactions, including bruising, dermatitis, discomfort, edema, erythema, hemorrhage, inflammation, mass, pain, pruritus, swelling, urticaria, vesicles, and warmth (48%).
Increases in HDL, LDL, mean total cholesterol, and triglycerides.
Upper respiratory tract infection (26%); cough, sinusitis (9%).
Positive test for treatment-emergent binding antibodies (35%); infections (34%); malignancies.
Monitor for changes in the lipid profile.
Category C .
Safety and efficacy not established in children younger than 12 yr of age.
Impact unknown, but may result in increased risk of malignancies.
Risk of infection may be increased.
There have been no reports of overdosage.
Copyright © 2009 Wolters Kluwer Health.